According to Zhitong Finance App, Guangdong Wan Nianqing (301111.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 292 million yuan, an increase of 3.20% year on year; net profit attributable to shareholders of listed companies was 33.5017 million yuan, up 0.25% year on year; net profit attributable to shareholders of listed companies deducted non-recurring profit and loss of 236.232 million yuan, a decrease of 9.20% year on year; basic earnings per share were 0.21 yuan/share.
The company's profit distribution plan reviewed and approved by the board of directors is as follows: based on 160,000,000 shares, a cash dividend of 1 yuan (tax included) for every 10 shares, 0 bonus shares (tax included), and a capital reserve fund to transfer 0 shares for every 10 shares to all shareholders.
During the reporting period, the company was mainly engaged in R&D, production and sales of pharmaceuticals. It always adhered to the mission of “protecting human health with care”, insisted on being driven by innovation, took the development of traditional Chinese medicine as the main body, and actively laid out the fields of pharmaceuticals and chemicals in medical institutions. The company currently has 101 drug approval numbers, of which 32 are original research pioneers, 10 are exclusive varieties, 4 products are exclusive dosage forms, 16 products are included in the national basic drug catalogue, and 39 products are included in the national medical insurance catalogue. Currently, the main product line focuses on areas where traditional Chinese medicine has advantages such as biliary tract, hypoglycemic agents, cardiovascular and cerebrovascular drugs, colds, and supplements.